Zeo ScientifiX shifts to PPX, completes BioLumina buy amid cash strain and Exotropin dispute

Zeo ScientifiX, Inc. (PINK: BPSR) - quick read

What's happening: the clinical-stage biopharma is shifting sales mix toward its PPX™ service platform and topical/aesthetic products, completed the BioLumina asset purchase (June 25, 2025), signed supply commitments with a CDMO and a $1.0M subscription financing (250,000 shares) being paid in installments. Management is carrying heavy stock‑based compensation, added finance leases for lab equipment, and is in a commercial/legal dispute with affiliate Exotropin (termination notice; Exotropin disputes and demands). The company discloses substantial doubt about its ability to continue as a going concern.

Key points & statistics
- Three months ended July 31, 2025: Revenues $1,306,000; Cost of revenues $228,000; Gross profit $1,078,000; General & administrative $3,149,000; Net loss $(2,072,000).
- Nine months ended July 31, 2025: Revenues $3,545,000; Cost of revenues $675,000; Gross profit $2,870,000; G&A $7,588,000; Net loss $(4,706,000); Net loss per share (basic & diluted) $(0.74).
- Cash: $314,000 at July 31, 2025 (down from $657,000 at Oct. 31, 2024). Net cash used in operating activities for nine months: $(335,000).
- Balance sheet: Total assets $1,652,000; Total liabilities $3,966,000; Stockholders' deficit $(2,314,000). Accounts payable & accrued expenses: $2,422,000. Deferred revenue: $709,000. Convertible promissory notes (net of discount): $698,000. Finance lease obligations (current $28,000; total due through 2030 $119,000).
- Major customer concentration (three months ended 7/31/25): ~$257k (19.7%), ~$186k (14.3%), ~$144k (11.0%) to three large customers/distributors.
- Stock-based compensation: nine months $3,937,000 (non-cash). Unamortized stock compensation: restricted stock $554,000; options $670,000; warrants $1,678,000. Common shares outstanding ~6.50M; potential additional issuable shares: ~4.29M options/warrants and convertible debt convertible into up to 120,834 shares (plus possible 40,000 shares tied to BioLumina obligation).
- Recent activity: BioLumina asset purchase $200,000 (paid $25,000 cash + 30,000 restricted shares valued $75,000 + royalty/put structures); subscription agreement with accredited investor for 250,000 shares at $1.00 per share (payments in 10 monthly installments; two installments received and 50,000 shares issued).

Positive aspects of the income statement
- Revenue growth: Q3 2025 revenue $1,306,000 is +19.7% vs Q3 2024 ($1,091,000); nine‑month revenue up 5.0% YoY ($3,545,000 vs $3,376,000).
- Strong gross margins: gross margin ~82.5% for the quarter and ~81.0% for nine months - indicates product pricing and gross profitability on current sales mix.
- PPX™ platform traction: PPX sales increased materially (PPX = 27.8% of Q3 revenues vs 14.4% prior year quarter; nine‑month PPX $878,000 vs $326,000 prior year), showing diversification toward service offerings that are growing volume.

Negative aspects of the income statement
- Operating losses driven by G&A: G&A ($3,149,000 in Q3; $7,588,000 nine months) far exceed gross profit, largely driven by stock‑based compensation and professional fees; this non‑cash and cash expense mix is producing large operating losses.
- Large non‑cash stock compensation: $3,937,000 stock‑based comp in nine months inflates expenses and indicates dilution pressure; substantial unamortized compensation remains.
- Persistent net losses and cash strain: nine‑month net loss $(4,706,000) and cash balance of $314,000 create an urgent need for financing; liabilities exceed assets by ~$2.3M.
- Customer concentration and regulatory risk: a few large customers account for a meaningful portion of sales; products may face FDA HCT/P regulatory risk (company flags uncertainty), which could materially affect revenue ability.
- Legal/commercial risk: dispute with Exotropin over the Sales Agreement and the co‑developed product could interrupt revenue and lead to litigation or injunction risk (Exotropin demands the Company cease sales of the co-developed product).

Straightforward takeaway
- The business shows real top‑line momentum in PPX™ and healthy gross margins, but those positives are overwhelmed by outsized G&A and stock‑based compensation that produce material losses and growing liabilities.
- Liquidity is tight (cash $314k) and management discloses substantial doubt about going concern - the company will need near‑term financing or meaningful operating cash flow improvement to avoid distress or dilution.
- Key near‑term catalysts/risks to watch: resolution or escalation of the Exotropin dispute; receipt of remaining subscription payments and completion of CDMO milestones (deposits and minimum purchase orders); conversion/exercise activity on large outstanding option/warrant pools; any equity or debt raises (likely dilutive and costly).
- If you follow BPSR, treat it as high risk: early‑stage revenue traction but levered to financing, dilution and regulatory/legal outcomes.

Source: Zeo ScientifiX, Inc. Form 10‑Q for quarter ended July 31, 2025 (figures quoted as presented in the filing).